AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10765864 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 24): All identifiable, irreversibly infected dentin was removed prior to the application of the bonding agent and restorative material.
Number of subjects: 48
Study 7669483 — intervention group
Group type: EXPERIMENTAL
Intervention: Food (eating)
Number of subjects: 61
Study 7669483 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (10 min i.v. infusion of 1 microgram min-1)
Number of subjects: 61
Study 7669483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (10 min i.v. infusion of 1 microgram min-1)
Number of subjects: 61
Study 7669483 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomazole (p.o. administration of 40 mg)
Number of subjects: 61
Study 7669483 — intervention group
Group type: EXPERIMENTAL
Intervention: Meribendan (p.o. administration of 40 mg)
Number of subjects: 61
Study 7669483 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (p.o. administration of 1200 mg)
Number of subjects: 61
Study 2285629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (2 x 10 mg capsules three times daily)
Number of subjects: 20
Study 2285629 — intervention group
Group type: COMPARATOR
Intervention: Nisoldipine (2 x 10 mg tablets once daily)
Number of subjects: 20
Study 7023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 1.5 mg/kg on day 1 + ARA‐C 2 mg/kg on days 1‐5 (R1)
Number of subjects: 60
Study 7023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (DNR) 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R2)
Number of subjects: 60
Study 7023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin-DNA complex 1.5 mg/kg on days 1 and 2 + ARA‐C 2 mg/kg on days 4‐8 (R3)
Number of subjects: 60
Study 7023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall remission frequency across all groups
Number of subjects: 60
Study 7023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of survival between R3 and R1
Number of subjects: 60
Study 7023715 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with DNR-DNA complex vs free DNR
Number of subjects: 60
Study 31862174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (SBP goal of <120 mmHg)
Number of subjects: 1255
Study 31862174 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group (SBP goal of <140 mmHg)
Number of subjects: 1255
Study 31862174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 1255
Study 30852711 — intervention group
Group type: EXPERIMENTAL
Intervention: High School Transition Program (HSTP), N=241
Number of subjects: 497
Study 30852711 — intervention group
Group type: COMPARATOR
Intervention: Control group, N=256
Number of subjects: 497
Study 28678966 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% CPC and 0.28% zinc lactate (test group)
Number of subjects: 120
Study 28678966 — intervention group
Group type: COMPARATOR
Intervention: 0.07% CPC (positive control)
Number of subjects: 120
Study 28678966 — intervention group
Group type: COMPARATOR
Intervention: Negative control mouthwash without CPC
Number of subjects: 120
Study 25729623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (200 µg)
Number of subjects: 0
Study 25729623 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine (5 mg)
Number of subjects: 0
Study 25729623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide + Levocetirizine
Number of subjects: 0
Study 23816671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg 2 h prior to induction of anesthesia and 75 mg twice daily for 2 post-operative days
Number of subjects: 40
Study 23816671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40
Study 23816671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20881443 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3%-dexamethasone 0.1%, 1 drop q.i.d.
Number of subjects: 145
Study 20881443 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin 0.3%-dexamethasone 0.1%, 1 drop q.i.d., plus ketorolac tromethamine 0.5%, 1 drop t.i.d.
Number of subjects: 145
Study 20881443 — intervention group
Group type: COMPARATOR
Intervention: Control group (tobramycin/dexamethasone)
Number of subjects: 145
Study 20881443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (tobramycin/dexamethasone plus ketorolac)
Number of subjects: 145
Study 20881443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study 20361645 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 0
Study 17426398 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gel + fluoridated dentifrice
Number of subjects: 30
Study 17426398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice
Number of subjects: 30
Study 17426398 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 30
Study 15328495 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical suspension of bacterial antigens (Lantigen B)
Number of subjects: 80
Study 15328495 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological solution)
Number of subjects: 80
Study 11176083 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (loading dose 1 microg/kg; maintenance infusion, 0.25 microg x kg(‐1) x min‐1)
Number of subjects: 40
Study 11176083 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (loading dose, 50 microg/kg; maintenance infusion, 1 microg x kg(‐1) x min‐1)
Number of subjects: 40
Study 9595857 — intervention group
Group type: EXPERIMENTAL
Intervention: TCR gamma/delta gene rearrangement in peripheral blood lymphocytes and cerebral white matter of MS patients
Number of subjects: 0
Study 9595857 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of V delta‐J delta rearrangement patterns
Number of subjects: 0
Study 7996800 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl intake (240 mmol NaCl per day for two weeks)
Number of subjects: 37
Study 7996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NaCl intake (40 mmol NaCl per day for 2 weeks)
Number of subjects: 37
Study 7996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Active kallikrein excretion
Number of subjects: 37
Study 7996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma atrial natriuretic peptide levels
Number of subjects: 37
Study 7996800 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between urinary kallikrein and plasma atrial natriuretic peptide
Number of subjects: 37
Study 3173600 — intervention group
Group type: EXPERIMENTAL
Intervention: imidazole-2-hydroxibenzoate
Number of subjects: 22
Study 3173600 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 28306685 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Treadmill Exercise (ATE)
Number of subjects: 20
Study 28306685 — intervention group
Group type: COMPARATOR
Intervention: Land-Based Exercise (LBE)
Number of subjects: 20
Study 27237769 — intervention group
Group type: EXPERIMENTAL
Intervention: IM IFN beta‐1a 30 mcg once weekly (full-dose group)
Number of subjects: 100
Study 27237769 — intervention group
Group type: EXPERIMENTAL
Intervention: IM IFN beta‐1a 15 mcg once weekly for 2 weeks then 30 mcg once weekly (titration group)
Number of subjects: 100
Study 24508036 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg gE/AS01B (one dose)
Number of subjects: 714
Study 24508036 — intervention group
Group type: EXPERIMENTAL
Intervention: 25μg gE/AS01B (two doses, two months apart)
Number of subjects: 714
Study 24508036 — intervention group
Group type: EXPERIMENTAL
Intervention: 50μg gE/AS01B (two doses, two months apart)
Number of subjects: 714
Study 24508036 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg gE/AS01B (two doses, two months apart)
Number of subjects: 714
Study 24508036 — intervention group
Group type: COMPARATOR
Intervention: 100μg gE/saline (two doses, two months apart)
Number of subjects: 714
Study 22730850 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein milk supplement
Number of subjects: 35
Study 22730850 — intervention group
Group type: COMPARATOR
Intervention: Higher carbohydrate supplement
Number of subjects: 35
Study 20414783 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A 2% drops
Number of subjects: 78
Study 20414783 — intervention group
Group type: COMPARATOR
Intervention: Polyvinyl alcohol 1.4% drops (Control)
Number of subjects: 78
Study 18498912 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of aceclofenac 100 mg
Number of subjects: 24
Study 18498912 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of aceclofenac 100 mg
Number of subjects: 24
Study 15342210 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1.5 mg/kg subcutaneous (s.c.) once daily
Number of subjects: 201
Study 15342210 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) intravenous (i.v.) adjusted to aPTT 1.5‐2.5 times control
Number of subjects: 201
Study 15342210 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 201
Study 15342210 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 201
Study 11249891 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg, uptitrated to 32 mg after 4 weeks
Number of subjects: 251
Study 11249891 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg, uptitrated to 10 mg after 4 weeks
Number of subjects: 251
Study 11249891 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 251
Study 11249891 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 251
Study 9972901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (4-min aortic cross-clamping and 6-min reperfusion)
Number of subjects: 56
Study 9972901 — intervention group
Group type: COMPARATOR
Intervention: Control group (only ischaemic insult of operating procedure)
Number of subjects: 56
Study 8049846 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (0.3 mg/m2 body surface area)
Number of subjects: 12
Study 8049846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study 3352886 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (steroids preoperatively and for 4 days postoperatively)
Number of subjects: 222
Study 3352886 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (steroids pre- and postoperatively for 1 day)
Number of subjects: 222
Study 3352886 — intervention group
Group type: COMPARATOR
Intervention: Group C (no steroids)
Number of subjects: 222
Study 30077820 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive results in pediatric ophthalmology studies
Number of subjects: 174
Study 30077820 — intervention group
Group type: COMPARATOR
Intervention: Negative results in pediatric ophthalmology studies
Number of subjects: 174
Study 28068207 — intervention group
Group type: COMPARATOR
Intervention: 5.25% sodium hypochlorite
Number of subjects: 128
Study 28068207 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite activated by diode laser
Number of subjects: 128
Study 28068207 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution activated by diode laser
Number of subjects: 128
Study 28068207 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution with methylene blue dye activated by diode laser
Number of subjects: 128
Study 28068207 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (positive control)
Number of subjects: 128
Study 25724847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (3 mg, six 2-monthly oral doses over 1 year)
Number of subjects: 250
Study 25724847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 23464674 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-month treadmill and overground walking program (30 min, thrice per week)
Number of subjects: 102
Study 23464674 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-month treadmill and overground walking program (30 min, thrice per week)
Number of subjects: 102
Study 23464674 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study 20609398 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP(5)‐IPV/Hib administered concurrently with PCV7
Number of subjects: 0
Study 20609398 — intervention group
Group type: COMPARATOR
Intervention: DTaP(5)‐IPV/Hib administered at separate visits (staggered group)
Number of subjects: 0
Study 18028587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 135
Study 18028587 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 135
Study 16984993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone therapy (Intrinsa)
Number of subjects: 0
Study 16984993 — intervention group
Group type: COMPARATOR
Intervention: Oral methyltestosterone
Number of subjects: 0
Study 12622671 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of color-coded materials and Broselow Pediatric Emergency Tape in simulated resuscitations
Number of subjects: 28
Study 12622671 — intervention group
Group type: COMPARATOR
Intervention: Control scenarios without color coding
Number of subjects: 28
Study 10671676 — intervention group
Group type: EXPERIMENTAL
Intervention: CAV/PE‐W (dose‐intensive weekly alternating chemotherapy)
Number of subjects: 76
Study 10671676 — intervention group
Group type: COMPARATOR
Intervention: CAV/PE (standard alternating chemotherapy)
Number of subjects: 76
Study 9137950 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 3
Study 9137950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 8148854 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200 mg sustained-release
Number of subjects: 116
Study 8148854 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 200 mg sustained-release
Number of subjects: 116
Study 3484547 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital or primidone withdrawal
Number of subjects: 8
Study 3484547 — intervention group
Group type: COMPARATOR
Intervention: No drug change (control)
Number of subjects: 8
Study 3484547 — intervention group
Group type: COMPARATOR
Intervention: Addition or deletion of a single drug other than barbiturate
Number of subjects: 8
Study 29726280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis R0033
Number of subjects: 0
Study 29726280 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052
Number of subjects: 0
Study 29726280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum R0071
Number of subjects: 0
Study 29726280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27546373 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60mg/day
Number of subjects: 65
Study 27546373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 24447885 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse treatment
Number of subjects: 176
Study 22689417 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (750/1000 mg bid)
Number of subjects: 258
Study 20938175 — intervention group
Group type: EXPERIMENTAL
Intervention: Antofloxacin hydrochloride (400 mg loading dose on day 1, followed by 200 mg daily)
Number of subjects: 284
Study 20938175 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin (200 mg orally twice daily for 7-14 days)
Number of subjects: 284
Study 18549888 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLOC therapy (intra-abdominal vagal blocking)
Number of subjects: 31
Study 18549888 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLOC therapy
Number of subjects: 31
Study 15321783 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction intervention
Number of subjects: 146
Study 15321783 — intervention group
Group type: COMPARATOR
Intervention: Community educational standard of care
Number of subjects: 146
Study 11177300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin
Number of subjects: 0
Study 9076203 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (40 mg tablet)
Number of subjects: 20
Study 9076203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8360066 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 13
Study 8360066 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 13
Study 3759781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3 exposure for 1 hour over 4 consecutive days
Number of subjects: 8
Study 3759781 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA) exposure
Number of subjects: 8
Study 28253307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 126
Study 28253307 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 126
Study 28253307 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 126
Study 25663309 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity antenatal intervention (2-h psycho-educational programme)
Number of subjects: 83
Study 24384495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 5% 5‐fluorouracil (5‐FU) applied once every 2 weeks for a total of 16 weeks.
Number of subjects: 60
Study 24384495 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group).
Number of subjects: 60
Study 24384495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 5% 5‐fluorouracil (5‐FU) combined with cervical biopsy, Papanicolaou smear, and HPV results.
Number of subjects: 60
Study 22639944 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (eight weeks of weekly teacher-led yoga class and home-based daily yoga practice delivered by DVD)
Number of subjects: 40
Study 22639944 — intervention group
Group type: COMPARATOR
Intervention: Current best practice care (control group)
Number of subjects: 40
Study 22639944 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 40
Study 19573210 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia patient education for 3 months
Number of subjects: 60
Study 19573210 — intervention group
Group type: COMPARATOR
Intervention: Routine patient education for 3 months
Number of subjects: 60
Study 17295995 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with incentives I
Number of subjects: 66
Study 17295995 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with incentives II
Number of subjects: 66
Study 17295995 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 66
Study 15626318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss + Bio‐Gide membrane (test)
Number of subjects: 20
Study 15626318 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Gide membrane (control)
Number of subjects: 20
Study 10874062 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 77
Study 10874062 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 77
Study 10874062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 9349928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg per day)
Number of subjects: 20
Study 9349928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8195850 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim
Number of subjects: 60
Study 8195850 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 60
Study 2879344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HO) with diazepam (5 mg) in group I
Number of subjects: 49
Study 2879344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HO) in group II
Number of subjects: 49
Study 2879344 — intervention group
Group type: COMPARATOR
Intervention: Control group (group III)
Number of subjects: 49
Study 30982983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E pretreatment for 24 hours
Number of subjects: 0
Study 30982983 — intervention group
Group type: EXPERIMENTAL
Intervention: PIAS1-shRNA infection
Number of subjects: 0
Study 30982983 — intervention group
Group type: COMPARATOR
Intervention: High glucose and PA exposure
Number of subjects: 0
Study 29349539 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bundle with intraperitoneal lavage with antibiotic solution, fascial closure with Triclosan-coated sutures, and Mupirocin ointment application on skin staples
Number of subjects: 198
Study 29349539 — intervention group
Group type: COMPARATOR
Intervention: Standard bundle (Group 1)
Number of subjects: 198
Study 26936859 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation in infancy
Number of subjects: 1482
Study 26936859 — intervention group
Group type: COMPARATOR
Intervention: Placebo in pregnancy/Placebo in infancy
Number of subjects: 1482
Study 26936859 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in pregnancy/Iron in infancy
Number of subjects: 1482
Study 26936859 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron in pregnancy/Placebo in infancy
Number of subjects: 1482
Study 26936859 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron in pregnancy/Iron in infancy
Number of subjects: 1482
Study 25281223 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (0.5 or 1.0 mg/kg)
Number of subjects: 32
Study 25281223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23812296 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA silencing in control cells
Number of subjects: 0
Study 23812296 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA silencing in lipid-loaded VSMC
Number of subjects: 0
Study 23812296 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA acting as UPAR ligand
Number of subjects: 0
Study 23812296 — intervention group
Group type: COMPARATOR
Intervention: Control cells (not lipid-loaded)
Number of subjects: 0
Study 23812296 — intervention group
Group type: EXPERIMENTAL
Intervention: agLDL exposure
Number of subjects: 0
Study 23812296 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 0